In a recent issue of Clinical Science, Stanhewicz et al. investigated persistent microvascular dysfunction in women up to 16 months postpartum. The authors found sensitivity to the pressor effects of endothelin-1 (ET-1) was enhanced when compared with women who had a normotensive pregnancy. Importantly, the authors demonstrated that this effect was mediated via the endothelin type B (ETB) receptors. Therefore, the present study highlights the possibility that alterations in the localization of the ETB receptor contributes to the pathogenesis of pre-eclampsia and future cardiovascular disease (CVD) risk. Currently, there is great interest in the role of the endothelin system in pre-eclampsia. Targetting the endothelin system, potentially by modulating upstream pathways to prevent ETB receptor dysfunction, may improve health outcomes for women and their offspring during pre-eclampsia and later life.
Skip Nav Destination
Article navigation
January 2018
-
Cover Image
Cover Image
Oleic-acid-treated HepG2 cells immunostained for PGC-1α (PPARγ co-activator-1 α). In Clinical Science volume 132, issue 1, the results of work by Bernardi et al. include reporting that the protein TRAIL (TNF-related apoptosis inducing ligand) increases the expression of PGC-1α in HepG2 cells cultured with oleic acid. Overall, the article points to a potential therapeutic role for TRAIL against impaired glucose tolerance and non-alcoholic fatty liver disease; for details see pages 69–83.
Commentary|
January 02 2018
Endothelin type B (ETB) receptors: friend or foe in the pathogenesis of pre-eclampsia and future cardiovascular disease (CVD) risk?
Katrina M. Mirabito Colafella
1Cardiovascular Program, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Australia
2Department of Physiology, Monash University, Melbourne, Australia
3Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
Correspondence: Katrina M. Mirabito Colafella (katrina.mirabtio@monash.edu)
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
October 24 2017
Revision Received:
November 17 2017
Accepted:
November 20 2017
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2018
Clin Sci (Lond) (2018) 132 (1): 33–36.
Article history
Received:
October 24 2017
Revision Received:
November 17 2017
Accepted:
November 20 2017
Connected Content
Citation
Katrina M. Mirabito Colafella; Endothelin type B (ETB) receptors: friend or foe in the pathogenesis of pre-eclampsia and future cardiovascular disease (CVD) risk?. Clin Sci (Lond) 16 January 2018; 132 (1): 33–36. doi: https://doi.org/10.1042/CS20171366
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.